JP2020518641A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518641A5 JP2020518641A5 JP2019560665A JP2019560665A JP2020518641A5 JP 2020518641 A5 JP2020518641 A5 JP 2020518641A5 JP 2019560665 A JP2019560665 A JP 2019560665A JP 2019560665 A JP2019560665 A JP 2019560665A JP 2020518641 A5 JP2020518641 A5 JP 2020518641A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- antibody
- antigen
- antagonist
- aplnr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502621P | 2017-05-06 | 2017-05-06 | |
| US62/502,621 | 2017-05-06 | ||
| PCT/US2018/031255 WO2018208625A1 (en) | 2017-05-06 | 2018-05-04 | Methods of treating eye disorders with aplnr antagonists and vegf inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518641A JP2020518641A (ja) | 2020-06-25 |
| JP2020518641A5 true JP2020518641A5 (enExample) | 2021-06-10 |
| JP7161494B2 JP7161494B2 (ja) | 2022-10-26 |
Family
ID=62555166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019560665A Active JP7161494B2 (ja) | 2017-05-06 | 2018-05-04 | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3618876A1 (enExample) |
| JP (1) | JP7161494B2 (enExample) |
| KR (1) | KR102667021B1 (enExample) |
| CN (1) | CN110709104A (enExample) |
| AU (1) | AU2018266324B2 (enExample) |
| CA (1) | CA3062418A1 (enExample) |
| EA (1) | EA201992630A1 (enExample) |
| IL (1) | IL270267B2 (enExample) |
| MX (1) | MX389729B (enExample) |
| WO (1) | WO2018208625A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI887409B (zh) | 2020-05-11 | 2025-06-21 | 美商艾斯卡瓦公司 | 利用主要資料的局部性來有效率檢索已使用主要資料篩而被無損地縮減的資料 |
| CN115920057A (zh) * | 2023-01-03 | 2023-04-07 | 中国科学院合肥物质科学研究院 | 靶向aplnr蛋白棕榈酰化修饰的多肽及其在癌痛治疗中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0747045B2 (ja) | 1986-10-15 | 1995-05-24 | 株式会社大協精工 | 積層した注射器用滑栓 |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| JP3100727B2 (ja) | 1992-01-23 | 2000-10-23 | 株式会社大協精工 | 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品 |
| JP3172057B2 (ja) | 1995-04-05 | 2001-06-04 | 株式会社大協精工 | ラミネートゴム栓 |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| JP3512349B2 (ja) | 1999-01-29 | 2004-03-29 | 株式会社大協精工 | 柱状ゴム要素の成形型 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US7306799B2 (en) | 1999-06-08 | 2007-12-11 | Regeneron Pharmaceuticals, Inc. | Use of VEGF inhibitors for treatment of eye disorders |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
| JP2002209975A (ja) | 2001-01-19 | 2002-07-30 | Daikyo Seiko Ltd | 医薬バイアル用ラミネートゴム栓 |
| EP1613348B1 (en) * | 2003-03-12 | 2010-06-23 | The Arizona Board of Regents on Behalf of the University of Arizona | Methods for modulating angiogenesis with apelin compositions |
| CA2621047A1 (en) | 2005-02-02 | 2006-08-24 | Regeneron Pharmaceuticals, Inc. | Method of treating eye injury with local administration of a vegf inhibitor |
| PT2944306T (pt) | 2006-06-16 | 2021-02-15 | Regeneron Pharma | Formulações antagonistas de vegf adequadas para administração intravitreal |
| US8946382B2 (en) | 2009-02-27 | 2015-02-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Apelin peptides and methods of use |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2734546A1 (en) | 2011-07-18 | 2014-05-28 | Amgen Inc. | Apelin antigen-binding proteins and uses thereof |
| MX357393B (es) | 2012-01-23 | 2018-07-06 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti - ang2. |
| JP6181152B2 (ja) | 2012-04-11 | 2017-08-16 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | アペリン阻害剤としてのポリペプチドおよびその使用 |
| JP5775851B2 (ja) | 2012-06-27 | 2015-09-09 | 東京エレクトロン株式会社 | 塗布装置および塗布液充填方法 |
| TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EA201591700A1 (ru) * | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Гибридные белки апелина и их применение |
| EA201691027A1 (ru) | 2013-11-20 | 2016-12-30 | Ридженерон Фармасьютикалз, Инк. | Модуляторы aplnr и их применение |
| EP3120142B1 (en) | 2014-03-20 | 2018-12-19 | Centre National de la Recherche Scientifique (C.N.R.S.) | Compounds inhibiting apelin / apj / gp130 signaling for use for treating cancer by inhibiting cancer stem cells |
| US20160144025A1 (en) * | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| WO2017053807A2 (en) * | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
-
2018
- 2018-05-04 IL IL270267A patent/IL270267B2/en unknown
- 2018-05-04 JP JP2019560665A patent/JP7161494B2/ja active Active
- 2018-05-04 CA CA3062418A patent/CA3062418A1/en active Pending
- 2018-05-04 WO PCT/US2018/031255 patent/WO2018208625A1/en not_active Ceased
- 2018-05-04 AU AU2018266324A patent/AU2018266324B2/en active Active
- 2018-05-04 CN CN201880037918.XA patent/CN110709104A/zh active Pending
- 2018-05-04 EA EA201992630A patent/EA201992630A1/ru unknown
- 2018-05-04 EP EP18729829.4A patent/EP3618876A1/en active Pending
- 2018-05-04 KR KR1020197035953A patent/KR102667021B1/ko active Active
- 2018-05-04 MX MX2019012985A patent/MX389729B/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017536414A5 (enExample) | ||
| JP2010528047A5 (enExample) | ||
| JP2016504416A5 (enExample) | ||
| JP7403553B2 (ja) | 眼科の疾患の個別化された治療 | |
| JP5990511B2 (ja) | 血管新生に基づく眼障害の処置のための抗ｃｄ１６０特異的抗体 | |
| RU2014113046A (ru) | Профилактика и лечение патологических состояний глаз, вызванных комплементом | |
| JP2017502023A (ja) | 眼疾患を治療する組成物および方法 | |
| Al-Debasi et al. | Topical versus subconjunctival anti-vascular endothelial growth factor therapy (Bevacizumab, Ranibizumab and Aflibercept) for treatment of corneal neovascularization | |
| CN113166237A (zh) | 抗fam19a5抗体的用途 | |
| JP2020518641A5 (enExample) | ||
| JP6865581B2 (ja) | 神経学的疾患又は神経変性疾患に有用な新規抗体 | |
| JP5698534B2 (ja) | 改良されたｎｏｇｏ−ａ結合分子およびその医薬的使用 | |
| JP2011503094A5 (enExample) | ||
| WO2023001288A1 (zh) | 整合素GPIIb/IIIa拮抗剂及其和抗VEGF抗体联合用药的应用 | |
| JP7382343B2 (ja) | Ｍｆａｐ４に対する抗体 | |
| CN114450068A (zh) | 用于治疗急性神经炎性损伤的方法和剂 | |
| JP2018523673A5 (enExample) | ||
| IL301762A (en) | Methods and materials for the treatment of eye diseases | |
| JP2023533038A (ja) | 補体経路阻害剤及び血管新生阻害剤を含む融合タンパク質並びにその使用 | |
| TWI859339B (zh) | 抗nrp1a抗體及其用於治療眼或眼部疾病之用途 | |
| RU2022102753A (ru) | Fab ФРАГМЕНТ ГУМАНИЗИРОВАННОГО АНТИТЕЛА ПРОТИВ VEGF И ЕГО ПРИМЕНЕНИЕ | |
| JP2025501913A (ja) | 血管新生阻害剤結合抗Ｃ３ｂ抗体又は抗Ｃ５抗体及びその使用 | |
| TW202530256A (zh) | 多特異性抗原結合多肽之組合物及使用方法 | |
| CN118076637A (zh) | 缺氧诱导因子-1α抑制剂 | |
| Connolly et al. | Biologicals in Retinal Therapy |